Molecular Formula | C10H16N2O4S3 |
Molar Mass | 324.44 |
Density | 1.53±0.1 g/cm3(Predicted) |
Boling Point | 575.8±60.0 °C(Predicted) |
Solubility | DMSO: soluble5mg/mL (clear solution, warmed) |
Appearance | powder |
Color | white to beige |
pKa | pKa 6.35 (Uncertain);8.50 (Uncertain) |
Storage Condition | room temp |
Refractive Index | 1.626 |
Physical and Chemical Properties |
|
In vitro study | Component A, caused by an inward flux of CO2 and its subsequent hydration by CA-II, is blocked by Dorzolamide in a dose-dependent manner with an 50% inhibitory concentration IC 50 of 2.4 μM (95% confidence interval: 0.5-10.85 μM). |
In vivo study | Dorzolamide (3, 10, or 30 mg/kg/day, ip) synergized mitomycin C exhibits anti-tumor activity in EAC solid tumor models. Dorzolamide produces a dose-dependent decrease in the calculated ratio (relative value of 57.3±1, 25.5±1.8, and 24.3± 0.7 %, respectively). Animal Model: Female Swiss albino mice (EAC solid tumor). Dosage: 3, 10, or 30 mg/kg/day (synergized mitomycin C). Administration: IP, daily for 3 weeks. Result: Upregulated TXNIP and p53 while downregulated bcl-2. Effective in retarding the growth of EAC in mice. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
RTECS | XJ9095169 |
4-hydroxy 5,6-= hydro-6-tetra-4h-thieno [2,3-b] thiane-7, 7-= oxide mixed with acetonitrile, the reaction is carried out by slowly adding concentrated sulfuric acid, and the obtained product is sulfonated with chlorosulfonic acid or sulfuric acid, and then reacted with thionyl chloride to convert to sulfonyl chloride. The material in Tetrahydrofuran, the addition of ammonia, reaction to obtain sulfonamide, after reduction, that is to obtain the product, hydrochloric acid to obtain its hydrochloride.
developed by Merck Co, Inc., USA, was first launched in the United States in 1995. Carbonic anhydrase inhibitors. For the treatment of glaucoma.